Multispectral Imaging Collaboration
Nuclea Biomarkers, LLC and Dana Farber Cancer Institute (DFCI) will collaborate in research using Multi Spectral Imaging Techniques in the Oncology field. The collaboration will involve Massimo Loda, MD, a Pathologist and Researcher in the Adult Oncology Research Unit of DFCI and will utilize Multi Spectral Imaging techniques to identify certain genes and proteins that are involved in tumor formation, progression and metastasis.
Gene Expression and Array Comparative Genomic Hybridization
Nuclea Biomarkers, LLC and Dana Farber Cancer Institute (DFCI) will collaborate in research using Gene Expression and Array Comparative Genomic Hybridization Techniques in the Oncology field. The collaboration will involve Researchers in the Adult Oncology Research Unit of DFCI and will utilize Gene Expression and Array Comparative Genomic Hybridization techniques to identify certain gene signatures that are involved in tumor formation, progression and metastasis.
Technology Description
The mechanism of cancer progression involves chromosomal aberrations, including amplification of oncogenes and deletion of tumor suppressor genes. Microarray-based comparative genomic hybridization (array-CGH) is uniquely well suited for high-resolution detection of DNA copy number aberrations. This technology features a database of array-CGH data focused on genomic alterations in human and mouse cancer genomes. This database contains cancer profiles of melanoma, glioblastoma multiforme, multiple myeloma, pancreatic adenocarcinoma and lung adenocarcinoma.
Applications/Advantages
Since chromosomal aberrations play a pivotal role in cancer progression, knowledge of these genetic imbalances promises to lead to improved cancer diagnoses and treatments. These chromosomal aberrations are best revealed via array-CGH analysis. Array-CGH provides high-resolution estimates of copy aberrations, and can be performed efficiently on many samples. The data provided by array-CGH are quantitative measures of the DNA sequence dosage increase. Moreover, array-CGH can be performed with primary tumor tissue, circumventing issues with tumor cell cultures.
Licensing Agreement
Nuclea and Clark University have entered into an exclusive licensing agreement for access to a new inflammation mouse model. This mouse model will be useful in the respiratory sciences and research in Asthma and COPD.This mouse model has full genome profiling via current genomic technologies.
SPRING 2008
DFCI Impact Spring 2008 Nuclea Biomarkers Drives Study into the Molecular Pathology of Cancer
04/10/08
NUCLEA BIOMARKERS ANNOUNCES THAT IT HAS RECEIVED A U.S. PATENT ON "KINASE PEPTIDES AND ANTIBODIES"
7/15/07
NUCLEA BIOMARKERS RENEWS RESEARCH COLLABORATION WITH DANA FARBER CANCER INSTITUTE
06/05/06
Nuclea Biomarkers Announces it has Received a Notice of Allowance for U.S. Design Patent
08/10/05
Nuclea Biomarkers Establishes Research Collaboration with Dana Farber Cancer Institute
03/08/06 - Berkshire Economic Development Corporation
Biotech firm on its way
Nuclea Biomarkers, LLC is a biotechnology services company that has developed a novel technology platform to improve greatly the efficiency of drug discovery research.
Using the Company's extensive libraries of genetic, molecular, and outcomes data and data-mining services, research professionals in pharmaceutical and life sciences companies are able to focus time and money on the most promising paths for diagnosing and treating a broad range of diseases.
